The shares of the company that manufactures and supplies Iodine Derivatives gained around 10 percent to a 52-week high price of Rs 392.65 apiece on Thursday following the announcement of bonus issue to shareholders.
Infinium Pharmachem Ltd shares were trading at Rs 388.45 at 12:55 p.m., up Rs 30.85 or 8.63 percent from the previous close price, with a market value of Rs 270 crores.
According to the company’s NSE report, On August 2,2023, the board of directors approved the Bonus Issue of Equity Shares in a 1:1 ratio, That is, for every one share owned by existing shareholders, the company would issue one bonus share. The Company has set September 13, 2023 as the Record Date for determining the Company’s list of shareholders eligible for bonus equity share issuance.
The company’s operating margins have increased from 12.24 percent to 15.06 percent, while net profit has increased from 7.43 percent to 9.03 percent.Similarly, the company’s return on equity stands at 42.16 percent, and its return on capital employed at 52.03 percent.
In the previous three months, the stock has increased by 90 percent, and in the last month, it has increased by 43 percent.
Infinium Pharmachem Ltd revenue rose by 36 percent year on year, rising from Rs 71 crore in FY 21-22 to Rs 101 crore in FY 22-23. During the same time period, net profit increased by 80 percent, from Rs 5 crore to Rs 9 crore.
Infinium Pharmachem Limited is engaged in the exploration, manufacturing, and export of a diverse range of high-quality iodine derivatives used in pharmaceutical, chemical, biotech, and other related sectors across the globe.
Written by Omkar Chitnis
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
